Id: | acc3697 |
Group: | 1sens |
Protein: | SHIP |
Gene Symbol: | Inpp5d |
Protein Id: | Q92835 |
Protein Name: | SHIP1_HUMAN |
PTM: | phosphorylation |
Site: | Tyr1020 |
Site Sequence: | LTKPEMFENPLYGSLSSFPKP |
Disease Category: | Immune system diseases |
Disease: | Allergic |
Disease Subtype: | Lyn(-/-) |
Disease Cellline: | Lyn(-/-) BMMCs |
Disease Info: | |
Drug: | Lyn KO |
Drug Info: | "Lyn KO is a drug that might have specific effects on relevant biological pathways or diseases, but more context is needed for a detailed description." |
Effect: | modulate |
Effect Info: | "The study found that the phosphorylation level of the Src kinase Fyn was significantly increased in Lyn(–/–) BMMCs, while the phosphorylation and activity related to SHIP were significantly decreased, which may lead to an increase in the level of phosphatidylinositol 3,4,5 - trisphosphate and an enhancement of FcepsilonRI signaling. " |
Note: | Non-conventional drugs |
Score: | 3.0 |
Pubmed(PMID): | 15210764 |
Sentence Index: | 15210764_7 |
Sentence: | "The loss of SHIP phosphorylation and activity very likely contributes to the increased levels of phosphatidylinositol 3,4,5-trisphosphate and the excess FcepsilonRI signaling in Lyn(-/-) BMMCs." |
Sequence & Structure:
MVPCWNHGNITRSKAEELLSRTGKDGSFLVRASESISRAYALCVLYRNCVYTYRILPNEDDKFTVQASEGVSMRFFTKLDQLIEFYKKENMGLVTHLQYPVPLEEEDTGDDPEEDTVESVVSPPELPPRNIPLTASSCEAKEVPFSNENPRATETSRPSLSETLFQRLQSMDTSGLPEEHLKAIQDYLSTQLAQDSEFVKTGSSSLPHLKKLTTLLCKELYGEVIRTLPSLESLQRLFDQQLSPGLRPRPQVPGEANPINMVSKLSQLTSLLSSIEDKVKALLHEGPESPHRPSLIPPVTFEVKAESLGIPQKMQLKVDVESGKLIIKKSKDGSEDKFYSHKKILQLIKSQKFLNKLVILVETEKEKILRKEYVFADSKKREGFCQLLQQMKNKHSEQPEPDMITIFIGTWNMGNAPPPKKITSWFLSKGQGKTRDDSADYIPHDIYVIGTQEDPLSEKEWLEILKHSLQEITSVTFKTVAIHTLWNIRIVVLAKPEHENRISHICTDNVKTGIANTLGNKGAVGVSFMFNGTSLGFVNSHLTSGSEKKLRRNQNYMNILRFLALGDKKLSPFNITHRFTHLFWFGDLNYRVDLPTWEAETIIQKIKQQQYADLLSHDQLLTERREQKVFLHFEEEEITFAPTYRFERLTRDKYAYTKQKATGMKYNLPSWCDRVLWKSYPLVHVVCQSYGSTSDIMTSDHSPVFATFEAGVTSQFVSKNGPGTVDSQGQIEFLRCYATLKTKSQTKFYLEFHSSCLESFVKSQEGENEEGSEGELVVKFGETLPKLKPIISDPEYLLDQHILISIKSSDSDESYGEGCIALRLEATETQLPIYTPLTHHGELTGHFQGEIKLQTSQGKTREKLYDFVKTERDESSGPKTLKSLTSHDPMKQWEVTSRAPPCSGSSITEIINPNYMGVGPFGPPMPLHVKQTLSPDQQPTAWSYDQPPKDSPLGPCRGESPPTPPGQPPISPKKFLPSTANRGLPPRTQESRPSDLGKNAGDTLPQEDLPLTKPEMFENPLYGSLSSFPKPAPRKDQESPKMPRKEPPPCPEPGILSPSIVLTKAQEADRGEGPGKQVPAPRLRSFTCSSSAEGRAAGGDKSQGKPKTPVSSQAPVPAKRPIKPSRSEINQQTPPTPTPRPPLPVKSPAVLHLQHSKGRDYRDNTELPHHGKHRPEEGPPGPLGRTAMQ
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
INPP5D | ROSIPTOR | Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 activator | 3 | Unknown status | interstitial cystitis | ClinicalTrials |
INPP5D | ROSIPTOR | Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 activator | 3 | Unknown status | chronic interstitial cystitis | ClinicalTrials |
INPP5D | ROSIPTOR | Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 activator | 2 | Completed | atopic eczema | ClinicalTrials |
INPP5D | ROSIPTOR | Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 activator | 2 | Completed | chronic obstructive pulmonary disease | ClinicalTrials |
INPP5D | ROSIPTOR | Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 activator | 2 | Completed | interstitial cystitis | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.